Objective: The Nellix EndoVascular Aneurysm Sealing (EVAS) System (Endologix, Inc, Irvine, Calif) is a novel approach to abdominal aortic aneurysm (AAA) treatment whereby polymer is used to fill the AAA sac. We report 1-year results of the investigational device exemption pivotal trial.
The Nellix EndoVascular Aneurysm Sealing (EVAS) System (Endologix, Inc, Irvine, Calif) offers a novel approach to the treatment of abdominal aortic aneurysm (AAA). In contrast to traditional prostheses for endovascular aneurysm repair (EVAR), aneurysm sealing is achieved by means of polymer-filled endobags attached to covered stents that span the aortoiliac segment. The polymer-filled endobags function to seal the entire aneurysmal segment and to distribute fixation across the entire segment. This technique may address all potential sources (I, II, III, IV) of endoleak directly.
Normal and abnormal imaging appearances after standard EVAS are unique and described in a consensus document based on the collective experience of >1000 clinical cases. 1 Results of multiple observational cohorts outside the United States with the commercially approved Nellix device have been reported and describe excellent real-world outcomes, with low mortality and very low rates of endoleaks and secondary procedures. 2 We also recently reported that the 30-day safety end point of the investigational device exemption (IDE) trial of the Nellix device for EVAS was successfully achieved. 3 We now report 1-year results of the IDE trial for safety and efficacy.
METHODS
Nellix system and EVAS procedure. The Nellix EVAS System and its method of implantation have been recently described in detail. 2, 3 In brief, after the patient is anesthetized and given heparin for anticoagulation, arteriography is performed to establish the specific device length needed on each side to ensure full coverage of the Nellix device from the nonaneurysmal infrarenal segment to the nonaneurysmal common iliac segments. The Nellix 17F outer-diameter catheter is introduced via each femoral artery. Each device is positioned at the lowest renal artery inferior margin and terminates in the common iliac artery. After the Nellix catheters are positioned below the most caudal renal artery, the outer sheaths are retracted and the catheter connectors are attached to the console connectors. The stent balloons are simultaneously inflated with contrast-enhanced saline to deploy the covered stents. The endobags are prefilled with saline with pressure monitoring to determine the volume of polymer required to achieve adequate pressure and thus seal the aneurysm. The saline is withdrawn, and the volume aspirated is measured to determine the volume of polymer to be used. The polymer is injected into the endobags, and careful pressure manometry is used to fill the aneurysmal lumen to the target volume and pressure, thereby excluding and sealing the entire aneurysm. Angiography is performed to confirm stent patency and absence of endoleaks. The delivery systems are then detached from the implant and removed.
Clinical trial design. A prospective, multicenter, singlearm clinical study of the Nellix EVAS System was conducted at 29 sites under an IDE approved by the United States Food and Drug Administration. Local Institutional Review Board or Ethics Committee approval was obtained before patient enrollment at all sites (Supplementary  Table I , online only).
After written informed consent was obtained, each potential participant underwent screening by the local site and an imaging core laboratory (Cleveland Clinic Peripheral Vascular Laboratory, Cleveland, Ohio) as well as an independent medical reviewer. High-resolution computed tomography angiography (CTA) scanning was required #3 months of screening. In addition to anatomical eligibility, each patient underwent a physical examination, a medical history review, and selected blood laboratory analyses. Inclusion and exclusion criteria are summarized in Table I . Patients were re-evaluated at 1 month, 6 months, and 1 year with clinical evaluation and CTA scanning. All patients will subsequently be evaluated annually through 5 years of follow-up. The first patient at each site was designated a "roll-in" patient. Subsequently enrolled patients comprised the 150-patient trial cohort.
The primary safety end point definition is the incidence of major adverse events (MAEs) at 30 days as adjudicated by an independent Clinical Events Committee (CEC). MAEs included all-cause death, bowel ischemia, myocardial infarction, paraplegia, renal failure, respiratory failure, stroke, and procedural blood loss $1 L. Serious adverse events (SAEs) are defined as any adverse events resulting in death or serious deterioration in the health of the patient that resulted in life-threatening illness or injury, a permanent impairment, or required hospitalization or prolongation of an existing hospitalization. An independent Data Safety Monitoring Committee periodically reviewed safety data.
The primary effectiveness end point definition is the rate of treatment success at 1 year. Treatment success is defined as procedural technical success (intended deployment without unintentional coverage of both internal iliac arteries or any visceral aortic branches and successful removal of the delivery system) and freedom from AAA rupture during follow-up, open conversion, type I or III endoleak, sac enlargement, or intervention for migration or lumen stenosis/occlusion at 1 year. 
RESULTS

Compliance with follow-up
A total of 29 roll-in patients (1 per site) were enrolled for training purposes and were analyzed separately (Supplementary Table II , online only), and 150 patients were enrolled in the primary arm of the study. Of these patients, 144 (96%) were eligible to return for the 1-year follow-up visit and 143 (99.3%) returned. Five patients died before the 1-year visit was due (see details of mortality below). One additional patient withdrew consent before the 1-year follow-up. The core laboratory reviewed 100% of the images submitted by each site at each visit period.
Baseline patient characteristics
The study population reflects the general AAA population, which consists of elderly adults with multiple surgical risk factors. The average age was 73 years. Eight women were enrolled. The original version of the IDE study protocol only allowed subjects with a sac diameter of $5.5 cm. Because this criterion excluded most women, the protocol was amended to allow AAA with a sac diameter of $5 cm, or $4.5 cm if it had increased by $0.5 cm within the last 6 months, or which exceeded 1.5 times the transverse dimension of an adjacent nonaneurysmal aortic segment. The average maximum sac diameter (long axis) was 58 mm (range, 44-82 mm). The American Society of Anesthesiologists Physical Status Classification for most patients was III or IV, indicative of extensive comorbidity (Table II) .
Procedural characteristics
General anesthesia was used in 56%. Percutaneous access was used for 55% of the procedures. Mean polymer fill volume was 75 mL. Fluoroscopy time averaged 10 minutes. The average procedure time was 88 minutes (range, 50-205 minutes). Procedural technical success was 100%. Hospital length of stay averaged 1.1 days.
Safety outcomes at 30 days
The MAEs rate at 30 days was 2.7% (95% confidence interval [CI], 0.7%-6.7%), which was significantly lower than the SVS performance goal of 56% (P < .0001). CEC adjudication identified 4 patients (2.4%) with 6 MAEs by 30 days, including renal failure in 2, respiratory failure in 2, multiorgan failure in 1, and bowel ischemia in 1. The 30-day MAEs incidence was 1.4% (95% CI, 0.2%-5.0%) in men (n ¼ 142) and 25.0% (95% CI, 3.2%-65.1%) in women (n ¼ 8). Complete details of the 30-day safety results are reported elsewhere. Device-related SAEs Device-related SAEs occurred #30 days of the procedure in two patients (1.3%). In the first patient, a renal artery was inadvertently covered by a Nellix device. After the procedure, repeat review of the final angiogram identified delayed filling of the renal artery. The patient was returned to the operating room for attempted renal stenting, but recanalization could not be achieved. As a result, the patient experienced renal failure, although hemodialysis was not required. The second patient sustained intraoperative iatrogenic AAA rupture during the prefill step. Upon evacuating the prefill from the endobags, the patient's blood pressure was noted to be dropping as a result of presumed disruption of the aneurysm after pressurization of the sac during the prefill. The procedure was completed uneventfully by injecting polymer into the endobags as planned, achieving seal with no evidence of endoleak. Although retroperitoneal hematoma was confirmed on the postoperative CT, no additional complications occurred and the patient required no additional treatments.
Device-related SAEs occurring >30 days were noted in five patients (3.4%). Limb occlusions were seen in two patients (1.3%): one presented on day 285 and the other first presented on day 41 with subsequent limb occlusion on days 195 and 244. No particular etiology was found for the two limb occlusions, and no stent fracture or kinking was reported by the site or by the core laboratory for these two individuals. A type Ia endoleak was noted in one patient on a 30-day CT scan. This was treated with coils. The patient presented 7 months after the procedure with abdominal and back pain. CTA revealed a type Ia endoleak and periaortic stranding. The leak was retreated with coils and the addition of glue, without resolution. The device was explanted, and a contained aneurysm rupture was identified during the open conversion. The patient failed to thrive and died 1 month later in hospice care. A type Ia endoleak was noted in another patient on the 6-month follow-up CTA. This resolved after being treated with coil and glue embolization and continues to be free of endoleak through the 1-year follow-up.
The final patient was admitted to the hospital 9 months postprocedure for multiple infections and rectal bleeding. A device-related MAE, bowel (descending colon) ischemia, was adjudicated by the CEC. The patient sustained a stroke at 10.5 months and died w3 weeks later.
Outcomes at 1 year
Major adverse events. The MAEs rate at 1 year was 6.7% (95% CI, 1.0%-6.7%). The Kaplan-Meier freedom from MAEs estimate was 93.3% ( Supplementary Fig 1, online  only) . There were 16 MAEs in 10 patients, including death in 6, stroke in 3, bowel ischemia in 2, renal failure in 2, respiratory failure in 2, and myocardial infarction in 1.
Mortality. All-cause mortality through 1 year was 4.0% (n ¼ 6). The Kaplan-Meier freedom from mortality estimate was 96.0% ( Supplementary Fig 2, online  only) . Four patients died after 30 days from complications of lung cancer (n ¼ 2), hypertrophic cardiomyopathy (n ¼ 1), and stroke (n ¼ 1). Aneurysm-related mortality was 1.3% (n ¼ 2). The Kaplan-Meier freedom from aneurysm-related mortality estimate was 98.7% ( Supplementary Fig 3, online only) , which included two early deaths and one AAA rupture reported in follow-up ( Supplementary Fig 4, online only) . One patient underwent surgical conversion to open repair, which was performed for treatment of recurrent type Ia endoleak and aneurysm rupture. This patient subsequently died. Another patient with a history of congestive heart failure, emphysema, uncontrolled diabetes, morbid obesity, and prior pulmonary embolism died on postoperative day 4. The Nellix procedure was completed uneventfully, and she was discharged from the hospital on day 2. She suffered cardiac arrest at home and was found unresponsive; she was admitted emergently to the hospital where she continued to decline, developing multiorgan failure. CTA found the device intact and patent, with no evidence of endoleak or retroperitoneal hematoma. Because of the patient's history and poor prognosis, the family elected no further intervention.
Treatment success. The treatment success rate was 94.0% (126 of 134; 95% CI, 88.6%-97.4%), highly significant against the performance criteria (80%; P < .0001). Treatment success at 1 year was 95.3% (95% CI, 90.0%-98.2%) in men (n ¼ 127) and 71.4% (95% CI, 29.0%-96.3%) in women (n ¼ 7). There were 10 events in 8 patients including 1 (0.7%) AAA rupture during follow-up, 1 (0.7%) conversion to open repair, 5 (3.7%) secondary interventions, 2 (1.5%) aneurysm enlargements, and 1 (0.7%) type Ib endoleak. No migration >10 mm causing complications or requiring secondary intervention, or type III endoleaks were noted at 1-year follow-up.
Stent thrombosis. Stent thrombosis was observed in two patients (1.3%). One of these patients, notably with a body mass index of 54 kg/m 2 , suffered three thrombotic events of unclear etiology, ultimately treated with relining of the affected Nellix limb with another endograft and adjunctive anticoagulation. Endoleak. Endoleaks by type and follow-up interval are reported in Table III . At 1 year, endoleak incidence was 0.8% for type I, 2.3% for type II, and 0% for type III or IV.
Migration. Migration of >10 mm was observed in three of 129 (2.3%) patients at 1 year. None of these individuals presented with aneurysm sac expansion or had an endoleak or a secondary intervention.
Aneurysm sac morphology changes. Compared with the 1-month baseline, AAA sac diameter increased >5 mm in 2 patients (1.5%), remained stable (<5 mm change) in 129 patients (94.9%), and decreased in 5 patients (3.7%). In the two patients with sac enlargement (8.1 mm and 5.4 mm, respectively), no endoleaks were observed, and secondary intervention was not performed.
Secondary procedures. Six secondary procedures were performed in five patients (3.3%) through 1 year for treatment of type Ia endoleak (n ¼ 2), AAA rupture during follow-up (n ¼ 1), limb occlusion (n ¼ 2), and inadvertent renal artery coverage (n ¼ 1; Supplementary Fig 5,  online only) .
Surgical conversion. One patient (previously described) required surgical conversion, which was a relatively straightforward procedure compared with the removal of a conventional endograft with suprarenal fixation. The Kaplan-Meier estimate of freedom from surgical conversion was 99.3% ( Supplementary Fig 6, online only) .
DISCUSSION
This report presents 1-year outcomes from the prospective multicenter Nellix EVAS IDE study. The primary safety hypothesis tested in the Nellix EVAS IDE study was the rate of MAEs at 30 days relative to a performance goal of 56% (SVS open surgical control). The primary safety end point was satisfied with an MAEs rate of 2.7% at 30 days (95% CI, 0.7%-6.7%; P < .0001). The primary effectiveness hypothesis was defined as treatment success >80%. The primary effectiveness end point was satisfied with treatment success at 1 year of 94.0% (95% CI, 88.6-97.4%; P < .0001).
Secondary safety and effectiveness outcomes provided additional supportive evidence of the clinical utility of the Nellix EVAS System. Through 1 year, key secondary outcomes included 6.7% MAEs, 4.7% device-related SAEs, 1.3% AAA-related mortality, 0.7% AAA rupture during follow-up, 3.3% secondary intervention, and 0.7% surgical conversion. These results indicate that the Nellix EVAS System is safe and effective for its intended use.
Generally, the results from this IDE trial are comparable to those reported in IDE trials of commercially available stent grafts. However, the incidence of type II endoleaks and secondary interventions is considerably lower in the Nellix EVAS Pivotal study compared with previous IDE studies. The incidence of type II endoleak at 1 year was 2.3% with the Nellix EVAS System vs 8.9% to 34.3% with other commercially available stent grafts. [5] [6] [7] [8] [9] This is clinically meaningful, because individuals with persistent type II endoleak have a higher risk for AAA expansion and secondary intervention. [10] [11] [12] In addition, secondary interventions through 1 year were 3.3% with the Nellix EVAS System compared with 5.1% to 11.1% for other devices. [5] [6] [7] [8] [9] 13, 14 These benefits are also noted in postmarket reports of experience with Nellix in real-world use, suggesting that these outcomes can be achieved outside the setting of an IDE trial among both straightforward and complex patient populations across a broad range of vascular anatomies. 2 Proximal type I endoleak was reported in two patients within the 6-month follow-up window. Root-cause analyses of the type Ia endoleaks as reported in contemporary literature suggest that most are related to patient selection, low device placement caudal to the optimum dealing zone, or underfilling of the endobags, or a combination of these. In the present series, the cause of the endoleaks is indefinitive; however, careful follow-up is advocated in case of endoleak progression, and treatment should include improving the proximal seal using coils in combination with liquid embolization.
Migration was observed in three patients (2.3%), using the SVS reporting standards definition of $10 mm of movement. Within the 1-year follow-up period, no new endoleaks occurred and no secondary procedures were performed in these three patients. The incidence of migration in this study is comparable to that in other EVAR IDE studies; however, the mechanisms of migration in EVAS are likely unique. In EVAR, fixation and seal are based on discrete points of contact within the aorta. Even small movement can result in loss of fixation and seal. In EVAS, fixation and seal are distributed across the entire aneurysm. Movement of Nellix stents is not necessarily indicative of movement of the EVAS seal, because the latter is accomplished by the polymer-filled endobags, not the stents. Stent migration may occur in areas with inadequate distribution of polymer surrounding angulated stents, especially in small-flow lumens adjacent to large thrombus volume. If movement does occur, however, the Nellix endobags continue to provide an opportunity for fixation and seal. Whether these initial movements of the Nellix represent a period of stabilization or whether it becomes progressive, is not clear.
The instructions for use require a minimum neck length of 10 mm and recommend placement of the Nellix stents at the level of the renal arteries. In this present series, the infrarenal neck lengths in the three patients experiencing migration >1 cm were 27 mm, 32 mm, and 59 mm, respectively. Careful follow-up is necessary to determine the natural history of migration in Nellix patients and what developments would warrant further intervention.
As with other IDE EVAR studies, the number of female participants was small, perhaps due to the initial AAA diameter eligibility criterion, and the performance of EVAS in female patients will require further study in protocols designed to examine this issue. Regarding outcomes in women with the Nellix EVAS System, two women experienced an MAE #30 days of treatment. The somewhat higher incidence of MAEs in women is not entirely unexpected because it is well established that women treated with EVAR have greater rates of mortality and morbidity. [15] [16] [17] [18] Still, the benefit of EVAR in women likely remains greater than with open surgical AAA repair, although additional research is warranted.
It is important to understand that these data represent the initial experience with a device and technique for the endovascular therapy for aortic aneurysms that is significantly different from conventional EVAR therapies. Rather than a procedural end point focused on imaging, EVAS demands careful attention to pressure-volume relationships and the careful achievement of a suprasystolic polymer pressure to achieve the durable sealing and fixation envisioned as the primary mechanism of this therapy. Other differences involve the behavior of long balloon-expandable stents in often tortuous anatomy and the interaction of the endobags and the stents, such that optimal stent position is maintained. It is also important to note that with EVAS, the AAA sac may shrink even when filled with polymer. Although the sac would not be expected to shrink beyond the volume of the endobag and stent structure, excluded intramural thrombus may still be resorbed, resulting in sac shrinkage.
This initial clinical study in the United States is challenged by the same learning curve issues experienced in the application of EVAR in its early years. Despite these challenges, the results of this study demonstrate EVAS outcomes that appear comparable to those of contemporary EVAR. Although only longer-term follow-up will determine the place of EVAS in clinical therapy, these early results are encouraging, and better technique and patient selection may contribute to improved outcomes in future studies. A unique potential risk of EVAS noted in this trial relates to the single case of bowel ischemia, which may have been related to attempts to adjust the position of the device after deployment of the balloon-expandable stents, with resulting atheroembolization. Repositioning the stents once they have been deployed can be challenging. Attempts to reposition the relatively stiff stents can potentially cause atheroembolization, manifested as colon or lower extremity embolic events. A second unique potential risk of EVAS is iatrogenic aortic rupture. The EVAS mechanism of action is an intentional pressurization of the aneurysm sac to exclude the entire treated segment. When performed according to protocol, the risk is small, with an observed incidence of 0.7% in the current study. However, attention to detail is important during the endobag filling technique because the pressurization occurs over a relatively small volume increment.
This study had several limitations worth noting. First, given that this was a single-arm study that used safety and effectiveness performance goals, comparative performance of EVAS vs EVAR cannot be directly evaluated. Second, because only eight women (5%) were included, further characterizing EVAS performance and durability in women in future studies will be important. Third, patient outcomes >1 year were not yet available, and therefore, long-term outcomes with EVAS are currently unknown. Finally, because this clinical trial enrolled highly selected patients at high-volume centers, these outcomes may not be generalizable to the typical AAA patient in real-world practice.
CONCLUSIONS
Outcomes with the Nellix EVAS System are encouraging, with very low morbidity and mortality and high procedural and treatment success. The primary safety and effectiveness end points have been achieved. Continued follow-up is in progress and will be essential for evaluation of the long-term results and durability of the device and the EVAS procedure. 
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